The role of long noncoding RNA CRNDE in normal physiology and cancer
长链非编码RNA CRNDE在正常生理和癌症中的作用
基本信息
- 批准号:10715065
- 负责人:
- 金额:$ 48.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AllelesAlternative SplicingAnimal ModelAnimalsBindingBiogenesisBiologyBone Marrow TransplantationBreedingCRISPR interferenceCancer BiologyCancer PatientCause of DeathCell LineCell NucleolusCell ProliferationCell modelCharacteristicsCodeCollaborationsColorectal NeoplasmsConstitutionConstitutionalCustomCytoplasmDataDevelopmentDiagnosisDiseaseElementsGenesGenetic EngineeringGenomicsGrowthHematopoieticHematopoietic NeoplasmsHumanImpairmentKnockout MiceKnowledgeLengthLibrariesMalignant - descriptorMalignant NeoplasmsMapsMediatingMolecularMolecular Mechanisms of ActionMusNucleotidesPancreasPathogenesisPathway interactionsPatientsPhenocopyPhenotypePhysiologicalPhysiologyPlayPredispositionProductionProliferatingProteinsProteomicsRNARenal Cell CarcinomaRenal carcinomaResearchResolutionResourcesRibosomal RNARibosomesRoleShwachman-Diamond syndromeTestingTissuesTranscriptTranslationsTumor PromotionUnited StatesUntranslated RNAVariantcancer cellcancer typedifferential expressioneffective therapyexperienceexperimental studyin vivoknock-downloss of functionmouse modelnovelnovel therapeutic interventionoverexpressionpatient derived xenograft modelprematurepreventregeneration modelskeletal abnormalitytherapeutic targettissue injurytissue regenerationtranscriptome sequencingtumortumor growthtumor progressionurologic
项目摘要
PROJECT SUMMARY
A growing body of evidence indicates that long noncoding RNAs (lncRNAs), a diverse class of non-protein-
coding transcripts >200 nucleotides in length, play important roles in the initiation and progression of cancer.
LncRNAs have been proposed to regulate all cancer hallmarks, but, in the vast majority of cases, their
molecular mechanisms of action remain poorly understood. This knowledge gap is a major impediment
towards realizing the potential of lncRNAs as therapeutic targets in cancer and other diseases. As in many
human malignancies, lncRNAs are frequently dysregulated in renal cell carcinoma (RCC). RCC is the most
common type of kidney cancer and the most lethal malignant urological tumor, with approximately 70,000 new
cases diagnosed annually in the United States. To date, most genomic studies of RCC (and other cancers)
have focused on identifying disease-associated alterations of protein-coding genes. Our understanding of the
molecular pathways regulated by lncRNAs in RCC, and the functional roles of these transcripts in this
malignancy, remains limited. We mined RNA-seq data from RCC patients to identify a set of 805 lncRNAs that
are commonly overexpressed in this tumor type. We generated a custom CRISPR interference (CRISPRi)
library targeting these lncRNAs and performed screens in multiple RCC cell lines to identify lncRNAs that are
essential for RCC cell proliferation. These experiments revealed that the lncRNA Colorectal neoplasia
differentially expressed (CRNDE) is required for growth of all tested RCC cell lines. Although this lncRNA has
been shown to be overexpressed and is associated with poor patient survival in RCC and other types of
cancer, its molecular function remains unclear. We identified a critical region of CRNDE that is necessary for
RCC cell proliferation and we identified proteins that interact with this sequence. We also generated novel
genetically-engineered alleles in mice that enable constitutional or conditional deletion of critical Crnde
sequences. In this proposal, we will leverage our new understanding of this lncRNA, and the novel resources
we have generated, in order to dissect the molecular function of CRNDE and define its role in normal
physiology and in RCC pathogenesis in vivo. These experiments will take advantage of our extensive
experience, and that of our collaborators, in evaluating noncoding RNA functions and RCC biology using
cellular and animal models. Successful completion of the proposed research will address two major knowledge
gaps in the fields of RNA biology and cancer biology: 1) our limited understanding of the molecular
mechanisms-of-action of lncRNAs; and 2) how these mechanisms are co-opted by cancer cells to promote
tumor growth, particularly in RCC. We anticipate that the principles revealed by these studies will be broadly
applicable to our understanding of the roles of other lncRNAs in cancer cells and may set the stage for
developing therapeutics that target CRNDE or the pathways it controls.
项目概要
越来越多的证据表明,长非编码 RNA (lncRNA) 是一类不同类型的非蛋白质-
编码转录本长度>200个核苷酸,在癌症的发生和进展中发挥重要作用。
LncRNA 已被提议调节所有癌症标志,但在绝大多数情况下,它们的
分子作用机制仍知之甚少。这种知识差距是一个主要障碍
实现lncRNA作为癌症和其他疾病治疗靶点的潜力。正如许多
在人类恶性肿瘤中,lncRNA 在肾细胞癌 (RCC) 中经常失调。 RCC 是最
肾癌的常见类型和最致命的泌尿系统恶性肿瘤,约有 70,000 例新发肾癌
美国每年诊断出的病例数。迄今为止,大多数肾细胞癌(和其他癌症)的基因组研究
专注于识别与疾病相关的蛋白质编码基因的改变。我们的理解
RCC 中 lncRNA 调节的分子途径,以及这些转录本在此过程中的功能作用
恶性程度仍然有限。我们挖掘了 RCC 患者的 RNA-seq 数据,以确定一组 805 个 lncRNA,
在这种肿瘤类型中通常过度表达。我们生成了定制的 CRISPR 干扰 (CRISPRi)
文库针对这些 lncRNA,并在多个 RCC 细胞系中进行筛选,以鉴定
对于 RCC 细胞增殖至关重要。这些实验表明,lncRNA 结直肠肿瘤
所有测试的 RCC 细胞系的生长都需要差异表达 (CRNDE)。虽然这个lncRNA有
已被证明过度表达,并且与 RCC 和其他类型的患者生存率较差有关
癌症,其分子功能仍不清楚。我们确定了 CRNDE 的一个关键区域,这是
RCC 细胞增殖,我们鉴定了与该序列相互作用的蛋白质。我们还生成了小说
小鼠体内的基因工程等位基因能够实现关键 Crnde 的宪法性或条件性删除
序列。在本提案中,我们将利用我们对这种 lncRNA 的新理解以及新颖的资源
我们已经生成,以便剖析 CRNDE 的分子功能并定义其在正常情况下的作用
生理学和 RCC 体内发病机制。这些实验将利用我们广泛的
以及我们的合作者在评估非编码 RNA 功能和 RCC 生物学方面的经验
细胞和动物模型。成功完成拟议的研究将解决两个主要知识
RNA生物学和癌症生物学领域的差距:1)我们对分子生物学的了解有限
lncRNA的作用机制; 2)癌细胞如何利用这些机制来促进
肿瘤生长,尤其是肾细胞癌。我们预计这些研究揭示的原则将得到广泛的应用
适用于我们对其他 lncRNA 在癌细胞中的作用的理解,并可能为
开发针对 CRNDE 或其控制途径的疗法。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Target-directed microRNA degradation regulates developmental microRNA expression and embryonic growth in mammals.
- DOI:10.1101/gad.350906.123
- 发表时间:2023-07-01
- 期刊:
- 影响因子:10.5
- 作者:Jones, Benjamin T.;Han, Jaeil;Zhang, He;Hammer, Robert E.;Evers, Bret M.;Rakheja, Dinesh;Acharya, Asha;Mendell, Joshua T.
- 通讯作者:Mendell, Joshua T.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua T Mendell其他文献
Joshua T Mendell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua T Mendell', 18)}}的其他基金
The intersection of RNA biology and tumor biology
RNA生物学与肿瘤生物学的交叉点
- 批准号:
8953055 - 财政年份:2015
- 资助金额:
$ 48.96万 - 项目类别:
The intersection of RNA biology and tumor biology
RNA生物学与肿瘤生物学的交叉点
- 批准号:
10213661 - 财政年份:2015
- 资助金额:
$ 48.96万 - 项目类别:
The intersection of RNA biology and tumor biology
RNA生物学与肿瘤生物学的交叉点
- 批准号:
9125799 - 财政年份:2015
- 资助金额:
$ 48.96万 - 项目类别:
Functional Evaluation of microRNAs in Pancreatic Neoplasia
microRNA 在胰腺肿瘤中的功能评估
- 批准号:
8464662 - 财政年份:2013
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
7915972 - 财政年份:2009
- 资助金额:
$ 48.96万 - 项目类别:
Functional Evaluation of microRNAs in Pancreatic Neoplasia
microRNA 在胰腺肿瘤中的功能评估
- 批准号:
7651550 - 财政年份:2009
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
8026614 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
8712397 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
8578048 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
正常和病理细胞生理学中 c-Myc 调节的 microRNA
- 批准号:
7766253 - 财政年份:2007
- 资助金额:
$ 48.96万 - 项目类别:
相似国自然基金
TRIM25介导的泛素化及ISGylation通过选择性剪接和糖代谢调控髓细胞分化
- 批准号:82370111
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
PRMT5选择性剪接异构体通过甲基化PDCD4调控肝癌辐射敏感性的机制研究
- 批准号:82304081
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ac4C乙酰化修饰的HnRNP L选择性剪接EIF4G1调控糖代谢重编程介导前列腺癌免疫检查点阻断治疗无应答的机制研究
- 批准号:82303784
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
由CathepsinH介导的YAP选择性剪接在辐射诱导细胞死亡及辐射敏感性中的作用
- 批准号:82373527
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
拟南芥剪接因子SR蛋白通过选择性剪接调控获得性耐热的机理研究
- 批准号:32300247
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
- 批准号:
10717440 - 财政年份:2023
- 资助金额:
$ 48.96万 - 项目类别:
A Novel Long Noncoding RNA Associated with Systemic Lupus Erythematosus Pathogenesis
一种与系统性红斑狼疮发病机制相关的新型长非编码RNA
- 批准号:
10725130 - 财政年份:2022
- 资助金额:
$ 48.96万 - 项目类别:
Splicing Modulators for Rare Disease Indications
用于罕见疾病适应症的剪接调节剂
- 批准号:
10501840 - 财政年份:2022
- 资助金额:
$ 48.96万 - 项目类别:
A Novel Long Noncoding RNA Associated with Systemic Lupus Erythematosus Pathogenesis
一种与系统性红斑狼疮发病机制相关的新型长非编码RNA
- 批准号:
10537564 - 财政年份:2022
- 资助金额:
$ 48.96万 - 项目类别:
The role of CELF2 and its genetic variants in Alzheimer's disease
CELF2及其遗传变异在阿尔茨海默病中的作用
- 批准号:
10334445 - 财政年份:2021
- 资助金额:
$ 48.96万 - 项目类别: